Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

JPMorgan Chase is reportedly gearing up to accept spot Bitcoin ETFs as collateral for loans — a move that could open the floodgates for more crypto-backed lending on Wall Street. According to a ...

The decision follows recent developments in Regeneron’s obesity treatment pipeline. Trading near its 52-week low of $481.58, the stock has seen a sharp 18.6% decline in the past week. InvestingPro ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

JPMorgan Chase & Co. Chief Executive Jamie Dimon reiterated concerns raised last week about the U.S. fiscal outlook, saying on Monday that bond markets are "going to have a tough time" as a result ...

Samarcq brings extensive experience across the QIS ecosystem to his new position, and previously held the title of managing director, head of US cross asset and global FICC strategic indices ...

"There were market concerns of a faster unwind process," Giovanni Staunovo, commodity analyst at UBS, told clients in a note ... is yet to be felt in both economic growth and inflation, JPMorgan ...

“We think itepekimab’s disappointing data create a big challenge for REGN in the long term,” Wells Fargo analyst Mohit Bansal wrote. Bansal, who kept a PT of $580 per share, said investors ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 68.40% Upside ...